To ask the Secretary of State for Health and Social Care, if he will make it his policy to add Idiopathic CD4 Lymphopenia to the list of conditions that qualify for anti-viral drugs in the event that a patient is infected with covid-19.
Answered on
24 March 2022
The clinically eligible cohorts for antivirals have been determined by an independent expert group commissioned by the Department, which informed the development of a National Health Service clinical policy agreed by the United Kingdom Chief Medical Officers. Individual patients should contact their clinician to consider whether their condition or other criteria would determine their eligibility for treatments. A process for changes to this cohort is currently being considered. This will use emerging data and consider all factors which might impact eligibility for treatment. Any updates to the policy will be available in due course.